Five things for pharma marketers to know: Friday, August 4, 2017

1. The FDA approved a new drug to treat all forms of hepatitis C. AbbVie's Mavyret has an eight-week treatment regimen and a lower list price than Gilead Sciences' Harvoni, which costs around $94,000 for a full regimen. Mavyret costs about $26,400 for eight weeks and $52,800 for 16 weeks. (AP via the NYT)

A late-stage clinical study found that Eli Lilly's experimental acute migraine drug lasmiditan performed better than placebo. Analysts predict the migraine treatment market will hit an estimated $10 billion in 2025, up from $3 billion in 2015. (Reuters)

3. Fitbit told investors it plans to launch its long-awaited smartwatch in time for the holiday season. The watch will feature health and wellness tracking. (Pharmaphorum)